NET Cancer Day
May 14 2011
The US Food and Drug Administration (FDA) has approved Afinitor (everolimus) tablets for the treatment of progressive pancreatic neuroendocrine tumors in patients with unresectable, locally advanced or metastatic disease. This marks the first approval of a treatment for pNET patients in the United States in almost 30 years. According to Novartis, which manufactures the drug, approximately 60% of patients with pNET exhibit advanced disease at the time of diagnosis.